Suchergebnisse - "Stephenson, Joe J"

PubPharm (33)

1

A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma

enthalten in: Cancer chemotherapy and pharmacology | 2021

von Murray Stewart, T. | Von Hoff, D. | Fitzgerald, M. | +12

2

A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma

enthalten in: Cancer chemotherapy and pharmacology | 2020

von Murray Stewart, T. | Von Hoff, D. | Fitzgerald, M. | +12

3

A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma

enthalten in: Cancer chemotherapy and pharmacology | 2020

von Murray Stewart, T. | Von Hoff, D. | Fitzgerald, M. | +12

4

A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma

enthalten in: Cancer chemotherapy and pharmacology | 2020

von Murray Stewart, T. | Von Hoff, D. | Fitzgerald, M. | +12

5

Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations

enthalten in: The oncologist | 2020

von Bardia, A. | Gounder, M. | Rodon, J. | +12

6

Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3‐Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations

enthalten in: The oncologist | 2020

von Bardia, A. | Gounder, M. | Rodon, J. | +12

7

Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer

enthalten in: The Prostate | 2019

von Petrylak, D. | Kantoff, P. | Vogelzang, N. | +15

8

Phase 1 study of PSMA ADC, an antibody‐drug conjugate targeting prostate‐specific membrane antigen, in chemotherapy‐refractory prostate cancer

enthalten in: The Prostate | 2019

von Petrylak, D. | Kantoff, P. | Vogelzang, N. | +15

9

An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC)

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2017

von Awad, M. | Chu, Q. | Gandhi, L. | +10

10

An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC)

enthalten in: Lung cancer | 2017

von Awad, M. | Chu, Q. | Gandhi, L. | +10